Copyright © 2024 Research Nester. All Rights Reserved
Pneumococcal Vaccine Market size was over USD 8.13 billion in 2023 and is projected to reach USD 17.55 billion by 2036, witnessing around 6.1% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of pneumococcal vaccine is assessed at USD 8.53 billion.
Growth Drivers
Increased Revenue Generated by Pneumococcal Vaccine to Drive the Market Growth
Currently, there are only two pneumococcal vaccines approved by the U.S. Food and Drug Administration (FDA), Prevnar 13 and Pneumovax 23. Prevnar 13 is a pneumococcal 13-valent conjugate vaccine developed and manufactured by Pfizer. It is majorly used in children between the ages of 6 weeks and 5 years for providing active immunization for prevention of diseases caused by the Streptococcus pneumoniae bacteria. Pfizer reported a revenue of USD 5,847 million globally from Prevnar 13 in 2019 and a worldwide revenue of USD 5,802 million in 2018. In 2019, the vaccine segment observed an operational growth of 12% internationally on account of growing use in children. The increased volumes of vaccine purchased by governments is anticipated to be a driving factor for the market growth. Moreover, the association with Gavi, the Vaccine Alliance is further predicted to bring about a rise in the sale volumes.
Rising Research and Development Funding to Expand Pneumococcal Vaccine Market
The Meningitis Vaccine Project, a partnership between the World Health Organization and PATH, is a promising meningitis vaccine discovery program which is anticipated to provide a great opportunity for larger market players to enter into the pneumococcal vaccines market. This is another significant factor estimated to contribute towards the market growth in the next few years.
Challenges
Side Effects Associated with Pneumococcal Vaccines to Hinder the Market Growth
Various side effects are associated with the use of pneumococcal vaccine such as soreness, redness or swelling at the site of injection along with fatigue, headache, joint pain and fever is estimated to hamper the market growth. These side effects generally tend to be mild and the reactions get better within one or two days, however, serious reactions might occur at times which is predicted to decrease the adoption of the vaccine during the forecast period.
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.1% |
|
Base Year Market Size (2023) |
USD 8.13 billion |
|
Forecast Year Market Size (2036) |
USD 17.55 billion |
|
Regional Scope |
|
The market is segmented by vaccine, by age group, by end user and by region, out of which, the vaccine segment is bifurcated into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The segment for pneumococcal conjugate vaccine is anticipated to hold the largest share in the pneumococcal vaccine market on account of growing infant care awareness. Pneumococcal conjugate vaccine can be used against 13 types of pneumococcal bacteria. These vaccine are administered to infants at regular intervals till one year of age. The demand for pneumococcal vaccine is predicted to increase on account of growing pediatric population across the globe. The pneumococcal polysaccharide vaccine is anticipated to grow on the back of increasing administration among population above the age of 65.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others. The hospitals segment is estimated to hold the largest share in the market which can be attributed to growing healthcare infrastructure with rising number of hospitals which is anticipated to increase the demand for preventive vaccine around the world. On the other hand, the clinical segment is anticipated to grow at the highest rate over the forecast period as a result of increasing number of specialized and disease-specific clinics which is estimated to contribute to internal competition for better service and thereby raise the demand for pneumococcal vaccine.
Our in-depth analysis of the global market includes the following segments
|
By Vaccine |
|
|
By Age Group |
|
|
By End User
|
|
On the basis of regional analysis, the pneumococcal vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is expected to account for largest revenue share by 2036, backed by growing demand for efficient disease prevention vaccine across the region. Additionally, advanced research and development in healthcare sector in Asia Pacific that leads to manufacture of advanced and cost-effective vaccine is anticipated to drive the market growth in the region during the forecast period. The adoption of advanced and high end vaccine in developing regions such as China, India and Japan is increasing and in order to gain a competitive edge, the medical equipment manufacturers in this region are coming up with newer vaccine to prevent pneumococcal disorders.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?